This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dailey, C. F.
Right arrow Articles by Gibson, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dailey, C. F.
Right arrow Articles by Gibson, J. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2001, p. 2304-2308, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2304-2308.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus

Charlene F. Dailey,1,* Christine L. Dileto-Fang,1 Lewis V. Buchanan,1 Martha P. Oramas-Shirey,1 Donald H. Batts,2 Charles W. Ford,3 and John K. Gibson1

Pharmacology,1 Global Medical Affairs-Infectious Disease U.S.,2 and Biology I,3 Pharmacia, Kalamazoo, Michigan 49001

Received 6 December 2000/Returned for modification 2 March 2001/Accepted 1 May 2001

The efficacies of orally (p.o.) dosed linezolid and intravenously (i.v.) dosed vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in rabbits with experimental aortic-valve endocarditis were investigated. After endocarditis was established with a recent clinical MRSA isolate, rabbits were dosed for 5 days with linezolid (p.o., three times a day) at either 25, 50, or 75 mg/kg of body weight or vancomycin (i.v., twice a day) at 25 mg/kg. The 25-mg/kg linezolid group had a high mortality rate and bacterial counts in the valve vegetations that were not different from those of the controls. Linezolid dosed p.o. at 50 and 75 mg/kg and i.v. vancomycin produced statistically significant reductions in bacterial counts compared to those of the untreated controls. The reduced bacterial counts and culture-negative valve rates for the animals treated with linezolid at 75 mg/kg were similar to those for the vancomycin-treated animals. Concentrations of linezolid in plasma were determined at several points in the dosing regimen. These results suggest that the efficacy of linezolid in this infection model is related to trough levels in plasma that remain above the MIC for this microorganism. At the ineffective dose of linezolid (25 mg/kg) the concentration at sacrifice was 0.045 times the MIC, whereas the concentrations of linezolid in plasma in the 50- and 75-mg/kg groups were 2 and 5 times the MIC at sacrifice, respectively. The results from this experimental model suggest that the oxazolidinone linezolid may be effective for the treatment of serious staphylococcal infections when resistance to other antimicrobials is present.

* Corresponding author. Mailing address: Pharmacology 7250-209-205, Pharmacia & Upjohn, 301 S. Henrietta, Kalamazoo, MI 49001. Phone: (616) 833-1871. Fax: (616) 833-9763. E-mail: cfdailey{at}Pharmacia.com.

Antimicrobial Agents and Chemotherapy, August 2001, p. 2304-2308, Vol. 45, No. 8
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.8.2304-2308.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Boak, L. M., Li, J., Rayner, C. R., Nation, R. L. (2007). Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro Model. Antimicrob. Agents Chemother. 51: 1287-1292 [Abstract] [Full Text]  
  • Falagas, M. E., Manta, K. G., Ntziora, F., Vardakas, K. Z. (2006). Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58: 273-280 [Abstract] [Full Text]  
  • Athanassopoulos, G., Pefanis, A., Sakka, V., Iliopoulos, D., Perrea, D., Giamarellou, H. (2006). Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 654-657 [Abstract] [Full Text]  
  • Presterl, E., Grisold, A. J., Reichmann, S., Hirschl, A. M., Georgopoulos, A., Graninger, W. (2005). Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics. J Antimicrob Chemother 55: 45-50 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J. (2004). Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 48: 4665-4672 [Abstract] [Full Text]  
  • Fuda, C., Suvorov, M., Vakulenko, S. B., Mobashery, S. (2004). The Basis for Resistance to {beta}-Lactam Antibiotics by Penicillin-binding Protein 2a of Methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279: 40802-40806 [Abstract] [Full Text]  
  • Giacometti, A., Cirioni, O., Ghiselli, R., Orlando, F., D'Amato, G., Kamysz, W., Mocchegiani, F., Sisti, V., Silvestri, C., Lukasiak, J., Rocchi, M., Saba, V., Scalise, G. (2004). Temporin A Soaking in Combination with Intraperitoneal Linezolid Prevents Vascular Graft Infection in a Subcutaneous Rat Pouch Model of Infection with Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides. Antimicrob. Agents Chemother. 48: 3162-3164 [Abstract] [Full Text]  
  • Cha, R., Brown, W. J., Rybak, M. J. (2003). Bactericidal Activities of Daptomycin, Quinupristin-Dalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 47: 3960-3963 [Abstract] [Full Text]  
  • Chiang, F.-Y., Climo, M. (2003). Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 3002-3004 [Abstract] [Full Text]  
  • Dailey, C. F., Pagano, P. J., Buchanan, L. V., Paquette, J. A., Haas, J. V., Gibson, J. K. (2003). Efficacy of Linezolid plus Rifampin in an Experimental Model of Methicillin-Susceptible Staphylococcus aureus Endocarditis. Antimicrob. Agents Chemother. 47: 2655-2658 [Abstract] [Full Text]  
  • Humphrey, W. R., Shattuck, M. H., Zielinski, R. J., Kuo, M.-S. T., Biermacher, J. J., Smith, D. P., Jensen, J. L., Schaadt, R. D., Zurenko, G. E., Richards, I. M. (2003). Pharmacokinetics and Efficacy of Linezolid in a Gerbil Model of Streptococcus pneumoniae-Induced Acute Otitis Media. Antimicrob. Agents Chemother. 47: 1355-1363 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.-F., Potel, G., Bugnon, D. (2002). In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 46: 3706-3711 [Abstract] [Full Text]  
  • Miyazaki, S., Fujikawa, T., Kobayashi, I., Matsumoto, T., Tateda, K., Yamaguchi, K. (2002). The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother 50: 971-974 [Abstract] [Full Text]  
  • Yanagihara, K., Kaneko, Y., Sawai, T., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J.-I., Tashiro, T., Murata, I., Kohno, S. (2002). Efficacy of Linezolid against Methicillin-Resistant or Vancomycin-Insensitive Staphylococcus aureus in a Model of Hematogenous Pulmonary Infection. Antimicrob. Agents Chemother. 46: 3288-3291 [Abstract] [Full Text]  
  • Buchanan, L. V., Dailey, C. F., LeMay, R. J., Zielinski, R. J., Kuo, M.-S. T., Gibson, J. K. (2002). Time-dependent antibacterial effects of linezolid in experimental rabbit endocarditis. J Antimicrob Chemother 50: 440-442 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»